Results 31 to 40 of about 3,123 (163)
Dalbavancin for infective endocarditis: a single centre experience
, 2021 Infective endocarditis (IE) is a life-threatening disease, mostly caused by gram-positive cocci, needing a 4-6 weeks antibiotic course. Dalbavancin is a lipoglycopeptide active on gram-positive microorganisms, with a unique pharmacokinetic profile.
Boccia, Filomena +6 more
core +1 more source
Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS
, 2023 Dalbavancin is an antibiotic with activity against gram-positive bacteria that allows early discharge of patients requiring intravenous therapy. Outpatient treatment helps offset hospitalisation costs associated with standard intravenous treatment.
Iván Adán (14996961) +11 more
core +2 more sources
Dalbavancin: National Perceptions and Experiences Among Veterans Affairs (VA) Providers
Antimicrobial Stewardship & Healthcare EpidemiologyBackground: Dalbavancin is increasingly used for management of serious gram-positive infections, even beyond those for which it has formal FDA approval.
Michaela Barry +4 more
doaj +1 more source
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Frontiers in Microbiology, 2018 Background:Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole.
Dana Binyamin +9 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2020 Objective: To assess the safety and effectiveness of dalbavancin compared to standard of care (SOC) in the treatment of osteomyelitis in adults. Method: A retrospective cohort study of patients with osteomyelitis due to S. aureus treated with dalbavancin
Thamer A. Almangour +2 more
doaj +1 more source
Efficacy of Novel Antimicrobial Therapies for Treating Staphylococcus Infections in Wistar Rats
مجلة الانبار للعلوم البيطريةThe novel semisynthetic lipoglycopeptide dalbavancin has enhanced antibacterial action against a wide range of gram-positive bacteria. This study was conducted to evaluate the efficacy of dalbavancin in treating Staphylococcus Infections in ...
Noman D. Salih.
doaj +1 more source
, 2018 Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern.
Urania Rappo +5 more
core +1 more source
Effectiveness, safety and cost analysis of dalbavancin in clinical practice [PDF]
, 2020 OBJECTIVES: Dalbavancin is approved for the treatment of complicated skin and soft tissue infections. However, there is growing evidence that other gram-positive infections could be treated with this antibiotic.
Ortiz-Pérez, Sara +7 more
core +1 more source
Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series
Journal of Global Antimicrobial ResistanceBackground: Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics.
Kailey Ben-Sassi, Suhail Sarwar
doaj +1 more source
Dalbavancin as Consolidation Therapy in Elderly Patients
, 2023 20.500.12530/87873Objective: The goal of this study was to show the clinical characteristics, tolerability, safety and outcomes of geriatric patients treated with dalbavancin.
Rico-Nieto, Alicia +4 more
core +1 more source